These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10752558)

  • 21. Binding kinetics and substrate selectivity in HIV-1 protease-Gag interactions probed at atomic resolution by chemical exchange NMR.
    Deshmukh L; Tugarinov V; Louis JM; Clore GM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):E9855-E9862. PubMed ID: 29087351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.
    Mueller SM; Schaetz B; Eismann K; Bergmann S; Bauerle M; Schmitt-Haendle M; Walter H; Schmidt B; Korn K; Sticht H; Spriewald B; Harrer EG; Harrer T
    J Virol; 2007 Mar; 81(6):2887-98. PubMed ID: 17202219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
    Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
    J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of a G48H mutant of HIV-1 protease explains how glycine-48 replacements produce mutants resistant to inhibitor drugs.
    Hong L; Zhang XJ; Foundling S; Hartsuck JA; Tang J
    FEBS Lett; 1997 Dec; 420(1):11-6. PubMed ID: 9450540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigenic activity of three chimeric synthetic peptides of the transmembrane (gp41) and the envelope (gp120) glycoproteins of HIV-1 virus.
    Marin MH; Peña LP; Tanty CR; Higginson Clarke D; Arenas MA; Noguerol KR; León CS
    Prep Biochem Biotechnol; 2004 Aug; 34(3):227-37. PubMed ID: 15461139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
    Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
    Clin Exp Immunol; 1995 Feb; 99(2):175-81. PubMed ID: 7851008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
    Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
    Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1-infected individuals.
    Inami S; Taniguchi N; Ishibashi K; Nagao T; Aoki I; Ishii N; Okuda K
    AIDS; 1991 Sep; 5(9):1140-1. PubMed ID: 1930779
    [No Abstract]   [Full Text] [Related]  

  • 30. Geographical distribution of HIV-1 group O viruses in Africa.
    Peeters M; Gueye A; Mboup S; Bibollet-Ruche F; Ekaza E; Mulanga C; Ouedrago R; Gandji R; Mpele P; Dibanga G; Koumare B; Saidou M; Esu-Williams E; Lombart JP; Badombena W; Luo N; Vanden Haesevelde M; Delaporte E
    AIDS; 1997 Mar; 11(4):493-8. PubMed ID: 9084797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
    Kumar S; Seth P
    Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic profiling of substrate binding response to multidrug-resistant mutations in HIV-1 protease: Implication for combating drug resistance.
    Lv Y; Li J; Fang J; Jiao X; Yan L; Shan B
    J Mol Graph Model; 2017 Jun; 74():83-88. PubMed ID: 28371730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenic properties of phage displayed peptides comprising disulfide-bonded loop of the immunodominant region of HIV-1 gp41.
    Cano A; Viveros M; Acero G; Govezensky T; Munguia ME; Gonzalez E; Soto L; Gevorkian G; Manoutcharian K
    Immunol Lett; 2004 Sep; 95(2):207-12. PubMed ID: 15388262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epitope mapping of a monoclonal antibody which binds HIV-1 Gag and not the Gag-derived proteins.
    Sarubbi E; Denaro M
    FEBS Lett; 1993 Dec; 335(3):335-7. PubMed ID: 7505237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
    Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
    J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relevance of the reactivity of HIV 1 positive sera with synthetic peptides for understanding antigenic differences between circulating strains.
    Cernescu C; Ruţă SM
    Rev Roum Virol; 1993; 44(3-4):175-86. PubMed ID: 7826868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.